RxDoctor Payments Data

Sergey Kantsevoy

Gastroenterology · Baltimore, MDNPI 1912954181

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (56.1%), education and speaking fees — rather than concentrated in one kind of arrangement. Lumendi LLC accounts for 62.8% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2019 at $245,446 and has fallen 53.9% since, to $113,166 in 2025. Among gastroenterology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,097,809in general payments, 2019–2025

Across 966 payments — averaging $1136.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lumendi LLC$690K
  • Olympus Corporation Of The Americas$351K
  • Olympus America Inc.$26K
  • ERBE USA Inc$10K
  • Fujifilm Healthcare Americas Corporation$8K
  • Covidien LP$4K
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$616,02156%
  • Speaking & faculty fees$102,6569%
  • Grants$10,0001%
  • Travel & lodging$30,5173%
  • Food & beverage$13,4761%
  • Education$325,13930%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lumendi LLC124$689,590
Olympus Corporation Of The Americas456$350,516
Olympus America Inc.52$25,626
ERBE USA Inc2$10,123
Fujifilm Healthcare Americas Corporation10$8,185
Covidien LP2$4,250
AbbVie89$1,877
Apollo Endosurgery US Inc2$1,000
Olympus Corporation1$615
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC29$540
Boston Scientific5$437
Intercept Pharmaceuticals, Inc.19$374
QOL Medical, LLC13$328
Micro-tech Endoscopy USA, Inc.2$275
Mallinckrodt Hospital Products Inc.9$265
Conmed Corporation2$260
Medtronic3$249
Madrigal Pharmaceuticals8$218
Takeda Pharmaceuticals U.S.A., Inc.9$201
Eisai Inc.9$198
Nestle Healthcare Nutrition Inc.9$173
Sanofi6$155
Ferring Pharmaceuticals Inc.8$146
Aimmune Therapeutics, Inc.6$144
Phathom Pharmaceuticals, Inc.6$139
Shionogi Inc6$133
Pentax Of America, Inc.1$132
Exelixis Inc.7$130
Cook Medical LLC1$127
Digestive Care, Inc.4$121
Ardelyx, Inc.6$118
Alnylam Pharmaceuticals Inc.7$110
Ambu Inc.1$93
Ironwood Pharmaceuticals, Inc5$91
Johnson & Johnson(2 entities)3$76
Braintree Laboratories, Inc.3$55
Pfizer4$53
Lilly USA, LLC2$51
UCB, Inc.3$47
Romark Laboratories, LC3$47
Organon2$42
Dynavax Technologies Corporation3$42
Redhill Biopharma Inc.2$41
Vivus LLC2$41
Regeneron Healthcare Solutions, Inc.2$37
Dova Pharmaceuticals2$35
AstraZeneca2$34
Gilead2$30
Daiichi Sankyo Inc.1$27
Incyte Corporation1$26
Ipsen Biopharmaceuticals, Inc1$26
Evoke Pharma, Inc.1$24
Teleflex LLC1$23
Albireo Pharma, Inc.1$20
Novo Nordisk1$19
Mirum Pharmaceuticals, Inc.1$17
Boehringer Ingelheim1$16
Cumberland Pharmaceuticals, Inc.1$16
Shire North American Group Inc1$14
AMAG Pharmaceuticals, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,097,809 in reported general payments places this provider in the 95th percentile of 455 gastroenterology providers in Maryland.

See all gastroenterology providers in Maryland

Medicare billing

Part B allowed, 2024
$179,087
Medicare patients
392
Services billed
893

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates35$2,199
ClenpiqSod Picosulf/Mag Ox/Citric Ac12$2,064
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl100$1,417
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl38$602
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen11$563
Pantoprazole Sodium13$552
Sucralfate14$354
Metronidazole49$279
Ciprofloxacin Hcl52$219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ferring Pharmaceuticals Inc.Clenpiq$146$2,06412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 455 gastroenterology providers in Maryland.

Other gastroenterology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →